Pharma Journalist -

Harbour BioMed has entered into a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb aimed at advancing the discovery and development of…
Read More...

GSK has received U.S. Food and Drug Administration approval for Exdensur (depemokimab-ulaa), a new add-on maintenance treatment for patients aged 12 years and older with severe asthma…
Read More...

Alnylam Pharmaceuticals has announced plans to significantly expand its manufacturing footprint in Norton, Massachusetts, committing an investment of $250 million to build what it says…
Read More...

Astellas Pharma and Pfizer have reported positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial, strengthening evidence that the combination of PADCEV™…
Read More...

Takeda Pharmaceutical Company has announced positive topline results from two pivotal Phase 3 clinical trials evaluating zasocitinib (TAK-279), a next-generation oral therapy for adults…
Read More...

Johnson & Johnson has secured U.S. Food and Drug Administration approval for RYBREVANT FASPRO™, marking a significant advance in the treatment of epidermal growth factor receptor…
Read More...

Beren Therapeutics P.B.C., the parent company of Mandos LLC, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to…
Read More...

Telix Pharmaceuticals has announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and a global leader in radiation oncology, aimed at developing new…
Read More...

Zealand Pharma and OTR Therapeutics have entered into a multi-program strategic collaboration and licensing partnership aimed at discovering and developing a new generation of…
Read More...

Formation Bio and Lynk Pharmaceuticals have announced that Formation Bio has acquired worldwide rights—excluding Greater China—to LNK01006, a next-generation, central nervous system…
Read More...